The use of biomarkers to predict AD  

( Five strategies )

Please Help Support Alzheimer's Research Today! 
Your Alzheimer's donation will help billions live without it.
DONATE NOW

Intense multidisciplinary research has provided detailed knowledge of the molecular pathogenesis of Alzheimer disease (AD). This knowledge has been translated into new therapeutic strategies with putative disease-modifying effects. Several of the most promising approaches, such as amyloid-β immunotherapy and secretase inhibition, are now being tested in clinical trials. Disease-modifying treatments might be at their most effective when initiated very early in the course of AD, before amyloid plaques and neurodegeneration become too widespread. Thus, biomarkers are needed that can detect AD in the predementia phase or, ideally, in presymptomatic individuals. In this Review, we present the rationales behind and the diagnostic performances of the core cerebrospinal fluid (CSF) biomarkers for AD, namely total tau, phosphorylated tau and the 42 amino acid form of amyloid-β. These biomarkers reflect AD pathology, and are candidate markers for predicting future cognitive decline in healthy individuals and the progression to dementia in patients who are cognitively impaired. We also discuss emerging plasma and CSF biomarkers, and explore new proteomics-based strategies for identifying additional CSF markers. Furthermore, we outline the roles of CSF biomarkers in drug discovery and clinical trials, and provide perspectives on AD biomarker discovery and the validation of such markers for use in the clinic. To get more: http://www.nature.com

TODAY'S PHOTO

DHA contribute to normal brain development of the children

Supplements of the omega-3 fatty acid DHA (docosahexaenoic acid) may alter the function of the brain associated with working memory, according to results of a new study with healthy boys. ... http://www.nutraingredients.com

Беларусь ТВ

Posted YVN (AMYLOID @ PHOTO)